Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.
If you have finished surgery, chemotherapy, or radiation therapy, the question that often follows is what comes next. Many people look for ways to support their health and watch for recurrence, and some come across NK cell therapy, an immune cell therapy offered in Japan. This article explains how NK cell therapy relates to recurrence prevention, what it can and cannot be expected to do, and what to ask before you book a consultation at Grand Green Osaka Umekita Clinic in Osaka.
The short answer: a possible option to discuss, not a guarantee
NK cell therapy is sometimes chosen with the aim of preventing recurrence after cancer treatment or maintaining immune function. That aim describes an intention, not a promised result. No clinic can honestly say that an immune cell therapy will stop a cancer from returning, and you should be cautious about any source that does.
At Grand Green Osaka Umekita Clinic, NK cell therapy is provided as a self-pay (non-insured) treatment. Whether it makes sense for you depends on your cancer type, your stage, the treatment you have already had, your current health, and your own priorities. These points are best reviewed in person with a physician, ideally alongside the oncologist who knows your history.
Why recurrence and immune surveillance are linked in discussion
NK (natural killer) cells are a type of lymphocyte that circulates in the blood and can detect and attack abnormal cells, including cancer cells and virus-infected cells, without waiting for instructions from other immune cells. Researchers describe a process called immune surveillance, in which immune cells continually look for and remove abnormal cells before they can multiply.
It is thought that this surveillance can weaken with age, with long-term stress, and as a result of cancer itself. Treatments such as chemotherapy can also affect immune cells. The idea behind NK cell therapy is to return a larger number of activated NK cells in the hope of reinforcing a weakened immune function. This is a conceptual rationale. Research on immune cell therapy is ongoing, results in published studies vary, and a single study should never be read as proof that a therapy works for every person.
How the treatment works in practice
The therapy uses your own cells. A standard blood draw provides the NK cells, which are then activated and expanded at a licensed cell processing facility. The expanded cells are returned to your body by intravenous infusion. There is no hospitalization, and treatment is built around blood draws and infusions rather than surgery.
Because the cells are your own, the risk of rejection is considered low, and serious side effects have rarely been reported. Even so, temporary fever or fatigue may occur, and every medical treatment carries some risk. The number of sessions, the interval between them, and the overall plan should be explained to you in writing before you decide.
- A blood draw to collect your cells
- Activation and expansion at a specialized, licensed facility
- Return of the cells by IV infusion in the clinic
- Follow-up and review of how you are feeling
Working alongside your oncologist and standard care
NK cell therapy is not a replacement for standard cancer treatment. It is generally described as compatible with surgery, chemotherapy, and radiation therapy and may be used alongside them, but the decision should be made together with your cancer team. If you are in a surveillance phase after treatment, your oncologist’s follow-up schedule, scans, and blood tests remain the foundation of monitoring for recurrence.
Grand Green Osaka Umekita Clinic can coordinate with the medical institution that provides your standard treatment. It helps to bring a recent summary from your oncologist, including your diagnosis, stage, treatments received, and current medications. Please do not stop or delay any recommended treatment or check-up because you are considering an additional therapy.
Safety, regulation, and honest limits in Japan
In Japan, cell-based treatments like this are provided under the Act on the Safety of Regenerative Medicine, which requires a treatment plan to be submitted to and accepted by the authorities. This framework is about safety management and oversight. It does not mean that the effectiveness of the therapy has been established in the way that an approved, insured medicine has.
NK cell therapy is a self-pay treatment that is not covered by public health insurance, and costs can add up over several sessions. Fees, risks, side effects, and whether you are a suitable candidate should always be confirmed at a medical consultation. Be wary of anyone who offers a firm prediction of your outcome before examining you.
Questions to bring to your first consultation
A good consultation helps you leave with a clear picture rather than a sales pitch. Consider preparing questions in advance and writing down the answers so that you can share them with your family and your oncologist.
- What is the specific goal of treatment in my situation, and how will we judge whether it is worthwhile to continue?
- How many sessions are proposed, over what period, and what is the total cost including tests?
- What side effects might I experience, and who do I contact if I feel unwell after returning home?
- How will you share information with my oncologist, and what records will I receive?
- What are the limits of the evidence for my type of cancer?
International patients and people living in Japan can find information in English on the clinic’s multilingual information pages, and Osaka and Umeda are well connected for those traveling from other regions or countries. If you plan to travel, ask about scheduling, language support, and how follow-up will be handled after you return home.
Summary
NK cell therapy may be considered by some people who want to support immune function after cancer treatment, but it is a self-pay option with no guarantee of preventing recurrence. It is best understood as something to discuss with a physician, in addition to, never instead of, standard care and regular follow-up. If you would like to learn more, you can consult Grand Green Osaka Umekita Clinic in Osaka to review your situation, the costs, the risks, and the evidence before making a decision that feels right for you.
- Keep standard careFollow-up stays the foundation
- Consult a physicianSuitability is reviewed in person
- Confirm self-pay costsNot covered by insurance
- Check Japan's safety rulesRegenerative medicine plan
This figure is a conceptual diagram summarizing the article
References
- PubMed: Late complications and long-term care of adult CAR T-cell patients. (2024)
- PubMed: The critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM. (2026)
- PubMed: Quadruple immunotherapy with allogeneic natural killer cell infusion for recurrent neuroblastoma. (2026)
- PubMed: Adoptive cellular therapy after hematopoietic stem cell transplantation. (2024)
- PubMed: Intrathecal CRISPR-edited allogeneic IL-13Rα2 CAR T Cells for recurrent high-grade Glioma: preclinical characterization and phase I trial. (2026)
- PMC: Adoptive immunotherapy against ovarian cancer. (2016)
- PMC: Natural Killer Cell Recognition and Control of Epithelial Cancers. (2022)
- PMC: CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy. (2019)
- MHLW (Japan): Regenerative Medicine — Ministry of Health, Labour and Welfare, Japan
Supervising Physician
Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic
Hidenori Shimada
Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.
* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.